Company

*Boan Biotech Out-Licenses Japan Rights to Denosumab Biosimilar BA6101 in Upfront, Milestone, and Royalty Deal
BiosimilarsBoan Biotechnology

Boan Biotech Out-Licenses Japan Rights to Denosumab Biosimilar BA6101 in Upfront, Milestone, and Royalty Deal

Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that it has entered into a collaboration agreement with a partner for the Japan rights to its denosumab injection 60 mg (BA6101),…

Everest Medicines Signs Strategic Cooperation Agreement with Hi-Sen Pharmaceutical to Supply and Commercialize Six Products in China

Everest Medicines Signs Strategic Cooperation Agreement with Hi-Sen Pharmaceutical to Supply and Commercialize Six Products in China

InventisBio's Oral TYK2 Inhibitor Nomelcitinib Meets Primary Endpoint in Phase III Trial for Moderate-to-Severe Plaque Psoriasis – PASI 90 Above 70% at Week 16

InventisBio’s Oral TYK2 Inhibitor Nomelcitinib Meets Primary Endpoint in Phase III Trial for Moderate-to-Severe Plaque Psoriasis – PASI 90 Above 70% at Week 16

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
BeOne Medicines' Tislelizumab Receives Positive CHMP Opinion for NSCLC Treatment
BeiGeneBeOne Medicines

BeOne Medicines’ Tislelizumab Receives Positive CHMP Opinion for NSCLC Treatment

Bristol-Myers Squibb Gains NMPA Approval for Opdivo-Yervoy Combo in NSCLC
BMSBristol-Myers Squibb

Bristol-Myers Squibb Gains NMPA Approval for Opdivo-Yervoy Combo in NSCLC

Tibet Aim Pharm's Major Shareholder Transfers Stake to Beijing Fuhao
FinanceSHE: 002826

Tibet Aim Pharm’s Major Shareholder Transfers Stake to Beijing Fuhao

Roche's Elevidys Receives Negative CHMP Opinion for Duchenne Muscular Dystrophy
OTCMKTS: RHHBYRare / orphan disease drugs

Roche’s Elevidys Receives Negative CHMP Opinion for Duchenne Muscular Dystrophy

Show More